CRISPR

CRISPR1-chodl

ID

ZDB-CRISPR-200520-2

Name

CRISPR1-chodl

Previous Names

None

Target

chodl (1)

Sequence

5' - AGGATGCGCGCGACACTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ue105	chodl

Expression

Gene expression in Wild Types + CRISPR1-chodl

No data available

Phenotype

Phenotype resulting from CRISPR1-chodl

No data available

Phenotype of all Fish created by or utilizing CRISPR1-chodl

Phenotype	Fish	Conditions	Figures
horizontal myoseptum neuromuscular junction development process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	Fig. 2. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction increased area, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction area, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
thigmotaxis process quality, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. S4 from Oprişoreanu et al., 2019
CaP motoneuron presynapse assembly decreased process quality, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum synapse ab1-chrna labeling spatial pattern, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2, Fig. S3 from Oprişoreanu et al., 2019
horizontal myoseptum neuromuscular junction area, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse area, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development decreased process quality, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron axon decreased length, abnormal	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: indometacin	Fig. 2. from Oprişoreanu et al., 2021
motor neuron axon decreased branchiness, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 3 from Oprişoreanu et al., 2019
CaP motoneuron presynapse area, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
CaP motoneuron axon decreased length, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 1 from Oprişoreanu et al., 2019
horizontal myoseptum synapse morphology, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. S3 from Oprişoreanu et al., 2019
CaP motoneuron axon extension decreased process quality, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
horizontal myoseptum synapse ab-sv2 labeling spatial pattern, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2, Fig. S3 from Oprişoreanu et al., 2019
CaP motoneuron axon length, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron synapse assembly disrupted, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2 from Oprişoreanu et al., 2019
muscle pioneer synapse organization disrupted, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2 from Oprişoreanu et al., 2019
CaP motoneuron axon extension process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
axonogenesis involved in innervation disrupted, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 3 from Oprişoreanu et al., 2019
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
horizontal myoseptum neuromuscular junction development process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
horizontal myoseptum synapse znp-1 labeling increased distribution, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2 from Oprişoreanu et al., 2019
CaP motoneuron presynapse znp-1 labeling increased amount, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron presynapse increased area, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 4. , Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron synaptic assembly at neuromuscular junction process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 4. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: dipyridamole	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
synapse assembly disrupted, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 3 from Oprişoreanu et al., 2019
MiP motor neuron axon decreased length, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. S1 from Oprişoreanu et al., 2019
motor neuron axon truncated, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. S1 from Oprişoreanu et al., 2019
CaP motoneuron axon decreased length, abnormal	chodl^ue105/ue105; ml2Tg	control	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
CaP motoneuron axon length, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone	Fig. 2. from Oprişoreanu et al., 2021
axonogenesis disrupted, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 1, Fig. S1 from Oprişoreanu et al., 2019
CaP motoneuron presynapse znp-1 labeling amount, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: 8-hydroxy-5-quinolinecarboxylic acid	Fig. 5. from Oprişoreanu et al., 2021
CaP motoneuron axon extension process quality, ameliorated	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal	Fig. 2. , Fig. 3. from Oprişoreanu et al., 2021
horizontal myoseptum synapse znp-1 labeling spatial pattern, abnormal	chodl^ue105/ue105; ml2Tg	standard conditions	Fig. 2, Fig. S3 from Oprişoreanu et al., 2019
CaP motoneuron axon extension decreased process quality, abnormal	chodl^ue105/ue105; ml2Tg	chemical treatment by environment: indometacin	Fig. 2. from Oprişoreanu et al., 2021

Citations